Rapport Therapeutics, Inc. has announced the pricing of underwritten public offerings totaling approximately $175 million in common stock and $150 million in convertible notes. This significant financial move is designed to support the company’s ongoing clinical trials and research initiatives focused on neurological and psychiatric disorders.

The offerings are expected to close on or about October 30, 2026, subject to customary closing conditions. The company aims to utilize the net proceeds from these offerings primarily to fund its clinical trials and other research and development efforts, as well as for working capital and general corporate purposes.

Background

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, specializing in the discovery and development of small molecule precision medicines. The company operates under the SIC classification of 2834, which pertains to Pharmaceutical Preparations. Rapport is publicly traded on the Nasdaq under the ticker symbol RAPP.

What the Filing Says

According to the filing, Rapport is offering approximately $175 million of its common stock at an offering price of $21.00 per share. Additionally, the company is offering approximately $150 million in 2.25% convertible senior notes due 2032. The filing states, "The net proceeds from the common stock offering are expected to be approximately $187.5 million, and the net proceeds from the notes offering are expected to be approximately $145.0 million."

Impact

This funding initiative may significantly impact Rapport's ability to advance its lead investigational drug, RAP-219, which is designed to target specific neurological conditions. The offerings may also affect investors and stakeholders in the biotechnology sector, particularly those interested in companies focused on innovative treatments for neurological and psychiatric disorders.

What's Next

The offerings are expected to close on or around October 30, 2026, pending the satisfaction of customary closing conditions. The filing does not specify any further actions or developments following this date.